Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma

Cancer Research

Volumn 71, Issue 14, 2011, Pages 5040-5049

  Yang, Hong ^a   Robinson, Simon N ^a   Nieto, Yago ^a   Jones, Richard J ^b   Gocke, Christopher D ^c   Lu, Junjun ^a   Giralt, Sergio A ^a   Jones, Roy B ^a   Decker, William K ^a   Xing, Dongxia ^a   Steiner, David ^a   Champlin, Richard E ^a   McMannis, John D ^a   Ng, Jingjing ^a   Thomas, Michael W ^a   Shah, Nina ^a   Andersson, Borje S ^a   Parmar, Simrit ^a   Shpall, Elizabeth J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; RITUXIMAB; SYNDECAN 1;

ADHERENT CELL; ARTICLE; AUTOGRAFT; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BONE MARROW PURGING; CANCER COMBINATION CHEMOTHERAPY; CELL COUNT; CELL DIFFERENTIATION; CELL KILLING; CELL MATURATION; CELL NUCLEUS; CLONOGENESIS; COCULTURE; COLONY FORMING CELL; CONTROLLED STUDY; DRUG MECHANISM; EX VIVO GRAFT PURGING; EX VIVO STUDY; HUMAN; HUMAN CELL; INCUBATION TIME; MESENCHYMAL STEM CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; STEM CELL EXPANSION; THAWING;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW PURGING; BORONIC ACIDS; CELL LINE, TUMOR; CELL SEPARATION; HEMATOPOIETIC STEM CELLS; HUMANS; MAGNETICS; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PYRAZINES; TRANSPLANTATION, AUTOLOGOUS;

EID: 79960385474     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0842     Document Type: Article

References (39)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7. (Pubitemid 26240110)
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83. (Pubitemid 36532313)
3. Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, Litzow MR. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 1997;19: 337-42. (Pubitemid 27096065)
4. Ho J, Yang L, Banihashemi B, Martin L, Halpenny M, Atkins H, et al. Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2009;43:223-8.
5. Gahrton G, Svensson H, Bjorkstrand B, Apperley J, Carlson K, Cavo M, et al. Syngeneic transplantation in multiple myeloma-a casematched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1999;24:741-5.
6. Bashey A, Perez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, et al. Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant 2008;14:1118-24.
7. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after highdose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001;19:3771-9. (Pubitemid 32844791)
8. Bourhis JH, Bouko Y, Koscielny S, Bakkus M, Greinix H, Derigs G, et al. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica 2007;92:1083-90. (Pubitemid 350144215)
9. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after highdose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001;19:3771-9. (Pubitemid 32844791)
10. Szczepek AJ, Bergsagel PL, Axelsson L, Brown CB, Belch AR, Pilarski LM. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood 1997;89:1824-33. (Pubitemid 27097480)
11. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr., Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16. (Pubitemid 43882644)
12. Goel A, Dispenzieri A, Greipp PR, Witzig TE, Mesa RA, Russell SJ. PS- 341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp Hematol 2005;33:784-95. (Pubitemid 40826592)
13. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332-6. (Pubitemid 38326254)
14. Takishita M, Kosaka M, Goto T, Saito S. Cellular origin and extent of clonal involvement in multiple myeloma: genetic and phenotypic studies. Br J Haematol 1994;87:735-42. (Pubitemid 24264645)
15. Pilarski LM, Masellis-Smith A, Szczepek A, Mant MJ, Belch AR. Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma. Leuk Lymphoma 1996;22: 375-83. (Pubitemid 26341003)
16. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000;95:1056-65. (Pubitemid 30062731)
17. Yang H, Eaves C, de Lima M, Lee MS, Champlin RE, McMannis JD, et al. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts. Bone Marrow Transplant 2006;37:575-82. (Pubitemid 43378830)
18. Udomsakdi C, Eaves CJ, Swolin B, Reid DS, Barnett MJ, Eaves AC. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad SciUS A 1992;89:6192-6.
19. Petzer AL, Eaves CJ, Barnett MJ, Eaves AC. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood 1997;90:64-9. (Pubitemid 27276548)
20. Robinson SN, Ng J, Niu T, Yang H, McMannis JD, Karandish S, et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant 2006;37:359-66. (Pubitemid 43250469)
21. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991;3:207-12.
22. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95. (Pubitemid 27392702)
23. Rawstron AC, de Tute R, Jack AS, Hillmen P. Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemiaspecific assay for use in rituximab-containing regimens. Leukemia 2006;20:2102-10. (Pubitemid 44782835)
24. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257-317. (Pubitemid 38072572)
25. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68:190-7. (Pubitemid 351380120)
26. De Vos J, Bagnis C, Bonnafoux L, Requirand G, Jourdan M, Imbert MC, et al. Comparison of murine leukemia virus, human immunodeficiency virus, and adeno-associated virus vectors for gene transfer in multiple myeloma: lentiviral vectors demonstrate a striking capacity to transduce low-proliferating primary tumor cells. Hum Gene Ther 2003;14:1727-39. (Pubitemid 38010663)
27. Deola S, Scaramuzza S, Birolo RS, Cergnul M, Ficara F, Dando J, et al. Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells. J Transl Med 2007;5:35.
28. Hackney JA, Charbord P, Brunk BP, Stoeckert CJ, Lemischka IR, Moore KA. A molecular profile of a hematopoietic stem cell niche. Proc Natl Acad Sci U S A 2002;99:13061-6.
29. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003;425:836-41. (Pubitemid 37351467)
30. Etheridge SL, Spencer GJ, Heath DJ, Genever PG. Expression profiling and functional analysis of wnt signaling mechanisms in mesenchymal stem cells. Stem Cells 2004;22:849-60. (Pubitemid 39166941)
31. Kadereit S, Deeds LS, Haynesworth SE, Koc ON, Kozik MM, Szekely E, et al. Expansion of LTC-ICs and maintenance of p21 and BCL-2 expression in cord blood CD34(+)/CD38(-) early progenitors cultured over human MSCs as a feeder layer. Stem Cells 2002;20:573-82. (Pubitemid 35463070)
32. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991;77:2688-93.
33. Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 2001;91:1219-30. (Pubitemid 32267031)
34. Gregoretti MG, Gottardi D, Ghia P, Bergui L, Merico F, Marchisio PC, et al. Characterization of bone marrow stromal cells from multiple myeloma. Leuk Res 1994;18:675-82. (Pubitemid 24287825)
35. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007;21:1079-88. (Pubitemid 46672085)
36. Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, Holy X, et al. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma 2007;48:2032-41. (Pubitemid 47542991)
37. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A, et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007;21:158-63. (Pubitemid 44921847)
38. Ocqueteau M, Orfao A, Almeida J, Blade J, Gonzalez M, Garcia-Sanz R, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998;152:1655-65. (Pubitemid 28275024)
39. Mateo G, Corral M, Almeida J, Lopez-Berges C, Nieto J, Garcia- Marcos A, et al. Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma. Haematologica 2003;88:1013-21. (Pubitemid 37151152)